Agrawal YP. Low-dose naltrexone therapy in multiple sclerosis. Med Hypotheses 2005;64:721–724.
Cree BA, Goodin DS, Ross M, et al. Low dose naltrexone improves quality of life in patients with multiple sclerosis: a randomized, masked, placebo-controlled trial. Mult Scler 2008;14:S295.
Cree BA, Ross M, Violich I, et al. A single center, randomized, placebo-controlled, double-crossover study of the effects of low dose naltrexone on multiple sclerosis quality of life. Neurol 2008;70,Suppl1:A88.
Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008;14:1076-1083.
Rahn KA, Bonneau RH, Turel AP, et al. Opioid growth factor (OGF) and low dose naltrexone (LDN) inhibit immunological responses associated with EAE. Mult Scler 2008;14:S234.
Rahn KA, McLaughlin PJ, Bonneau RH, et al. Low-dose naltrexone (LDN) prevents development or delays onset and severity of experimental autoimmune encephalomyelitis in mice. Mult Scler 2008;14:S84-S85.
Smith JP, Stock H, Ringaman S, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol 2007;102:1-9.